Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
141
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway

Luke Carter-Brzezinskia Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Elizabeth Daviesa Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UKORCID Iconhttps://orcid.org/0000-0001-5424-6776
ORCID Icon,
Jane Normana Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Lourdes Rubioa Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Christopher Dixonb Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Sarah Bretta Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Tony Dunneb Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Shahid Iqbala Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Fiona L. Dignana Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Shazaad Ahmadc Department of Virology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Nicholas Machinc Department of Virology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Henry Morrissb Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
,
Anthony Wilsonb Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
&
Eleni Tholoulia Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UKCorrespondence[email protected]
 show all
Pages 3265-3267 | Received 17 May 2022, Accepted 27 Jul 2022, Published online: 22 Aug 2022

References

  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
  • El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: exploration and critical evaluation of the evidence to date. Br J Haematol. 2020;190(3):336–345.
  • Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327–338.
  • The King’s Fund Critical Care Services Audit; 2021 [cited 23 Sep 2021]. Available from: https://www.kingsfund.org.uk/publications/critical-care-services-nhs#bed-occupancy
  • NHS England – initial funding application – tocilizumab for treating cytokine release syndrome following CAR-T treatment (v1.2); 2022 [cited 28 Mar 2022]. Available from: https://www.blueteq-secure.co.uk/Trust/default.aspx
  • SARS-CoV-2 vaccination following haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy. Prepared by the British Society of Blood and Marrow Transplantation and Cellular Therapy Vaccination Sub-Committee (BSBMT-CT-VSC); 2021 [updated 2021 Nov 30].
  • Vairy S, Garcia JL, Teira P, et al. CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther. 2018;12:3885–3898.
  • Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood. 2020;136(1):137–139.
  • Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US Cancer Center Experience. Blood Adv. 2021;5(3):861–871.
  • Kuhnl A, Roddie C, Kirkwood AA, et al. Outcome of high-grade lymphoma patients treated with CD19 CART; updated real world experience in the UK. European Haematology Association Oral Presentation; 2020.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.